PLYMOUTH MEETING, Pa., June 1, 2020 /PRNewswire/ — Braeburn announces that it has requested final approval from the U.S. Food and Drug Administration (FDA) of the New Drug Application for Brixadi™ (buprenorphine) weekly and monthly…Original Article
Braeburn Submits Request for Final Approval of Brixadi (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
